Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy Patel AM; Moreland LWDrug Des Devel Ther 2010[Oct]; 4 (ä): 263-78The dawn of the biologic era has been an exciting period for clinical research and patient care in rheumatoid arthritis (RA). Targeted biologic therapies have changed the outcome of this disease and made remission a realistic outcome for many patients. Tocilizumab (TCZ, Actemra((R))), is a humanized monoclonal antibody against the interleukin 6 receptor and has been approved in many countries for the treatment of moderate to severe RA. There have been a number of important clinical trials demonstrating the efficacy of TCZ in active rheumatoid arthritis. This review summarizes the data on efficacy, patient-reported outcomes, adverse events, and safety from some of these trials. Current trends in clinical practice will be discussed. It is difficult to place TCZ and many new medications in the algorithm of treatment at present. However, the next few years will hopefully reveal their role as we better define abnormal immune processes in individuals with RA.|Algorithms[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/adverse effects/pharmacology/*therapeutic use[MESH]|Antirheumatic Agents/adverse effects/pharmacology/*therapeutic use[MESH]|Arthritis, Rheumatoid/*drug therapy/physiopathology[MESH]|Drug Delivery Systems[MESH]|Humans[MESH]|Receptors, Interleukin-6/antagonists & inhibitors[MESH] |